Recent observations on in vitro and in vivo preclinical studies on cell cultures and patient-derived xenografts (PDx) indicate that PARP inhibitors are effective in treating prostate and breast cancers, which are characterized by the loss of RAD51 foci [53]. Here, PARP1 is linked to breast cancer.